Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SP2086A
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SP2086A is an investigational pharmaceutical compound whose exact chemical identity, mechanism, and class have not been disclosed in publicly available sources. It is frequently studied together with SP2086 (likely related chemically or as a metabolite) and in combination therapies including fixed-dose combination (FDC) tablets alongside SHR3824 and metformin. The drug is being evaluated for pharmacokinetic properties and safety in healthy subjects, with a primary indication suggested for type 2 diabetes as part of FDC tablet studies. Detailed mechanistic, molecular, or pharmacological characterization is not available from public clinical trial records.[1][3]
- Other names
- SP2086ASP-2086ASP 2086A
Beyond the preview
Go deeper on SP2086A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SP2086A.